drugset / Trial / NCT00612014
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulimorelin | Small molecule | 40 ug/kg | Intravenous |
| Subject | Ulimorelin | Small molecule | 80 ug/kg | Intravenous |
| Subject | Ulimorelin | Small molecule | 160 ug/kg | Intravenous |
| Subject | Ulimorelin | Small molecule | 320 ug/kg | Intravenous |
| Subject | Ulimorelin | Small molecule | 600 ug/kg | Intravenous |